The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome
Open accessAbstract
PNPLA3 (adiponutrin, calcium-independent phospholipase A(2) epsilon [iPLA(2)ε]) is an adipose-enriched, nutritionally regulated protein that belongs to the patatin-like phospholipase domain containing (PNPLA) family of lipid metabolizing proteins. Genetic variations in the human PNPLA3 gene (i.e., the rs738409 I148M allele) has been strongly and repeatedly associated with fatty liver disease. Although human PNPLA3 has triacylglycerol (TAG) hydrolase and transacylase activities in vitro, its in vivo function and physiological relevance remain controversial. The objective of this study was to determine the metabolic consequences of global targeted deletion of the Pnpla3 gene in mice. We found that Pnpla3 mRNA expression is altered in adipose tissue and liver in response to acute and chronic nutritional challenges. However, global targeted deletion of the Pnpla3 gene in mice did not affect TAG hydrolysis, nor did it influence energy/glucose/lipid homoeostasis or hepatic steatosis/injury. Experimental interventions designed to increase Pnpla3 expression (refeeding, high-sucrose diet, diet-induced obesity, and liver X receptor agonism) likewise failed to reveal differences in the above-mentioned metabolic phenotypes. Expression of the Pnpla3 paralog, Pnpla5, was increased in adipose tissue but not in liver of Pnpla3-deficient mice, but compensatory regulation of genes involved in TAG metabolism was not identified. Together these data argue against a role for Pnpla3 loss-of-function in fatty liver disease or metabolic syndrome in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“NAFLD frequently occurs with other features of the metabolic syndrome (both in association with and independent of obesity) (4-6) and is the leading cause of liver disease in the Western world (4, 7, 8).”
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
A feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 14×
“For evaluation of the metabolic response to pharmacological activation of liver X receptor (LXR), a separate cohort of 12 week-old male mice was fed chow diet containing 0.025% of the potent LXR agonist T0901317 ( 48, 49 ) for 6 days (equivalent to 50 mg/kg of body weight/d) as described ( 38, 50 ).”
InfluentialSelf-citationSpeliotes, E. K., Butler, J. L., Palmer, C. D., Voight, B. F., & Hirschhorn, J. N. (2010) · Hepatology · doi:10.1002/hep.23768 · Cited by 362
Adipose triglyceride lipase deficiency causes tissue-specific changes in insulin signaling
Kienesberger, P. C., Lee, D., Pulinilkunnil, T., Brenner, D. S., Cai, L., Magnes, C., Koefeler, H. C., Streith, I. E., Rechberger, G. N., Haemmerle, G., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047787 · Cited by 120
Self-citation
Cited by
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Lipid Droplets and Cellular Lipid Metabolism
Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,661
FAT SIGNALS - Lipases and Lipolysis in Lipid Metabolism and Signaling
Zechner, R., Zimmermann, R., Eichmann, T. O., Kohlwein, S. D., Haemmerle, G., Lass, A., & Madeo, F. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.018 · Cited by 1,132
Self-citationNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Genetic deletion of this enzyme failed to induce NAFLD in mice (Basantani et al., 2011; Chen et al., 2010), while a PNPLA3 ASO decreased hepatic fatty acid esterification and protected fat-fed rats from NAFLD, PKCε activation, and hepatic insulin resistance (Kumashiro et al., 2013).”
Lipolysis: cellular mechanisms for lipid mobilization from fat stores
Grabner, G. F., Xie, H., Schweiger, M., & Zechner, R. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00493-6 · Cited by 765
Self-citationNonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
Birkenfeld, A. L., & Shulman, G. I. (2014) · Hepatology · doi:10.1002/hep.26672 · Cited by 738
Lipid droplets and liver disease: from basic biology to clinical implications
Gluchowski, N. L., Becuwe, M., Walther, T. C., & Farese, R. V. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.32 · Cited by 677
The role of lipid droplets in metabolic disease in rodents and humans
Greenberg, A. S., Coleman, R. A., Kraemer, F. B., McManaman, J. L., Obin, M. S., Puri, V., Yan, Q.-W., Miyoshi, H., & Mashek, D. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46069 · Cited by 621
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Insulin Resistance, Obesity and Lipotoxicity
Yazıcı, D., & Sezer, H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_12 · Cited by 499
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Mechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
Self-citationRegulation of adipocyte lipolysis
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J.-A., Fernández, S., & Rodríguez, A. (2014) · Nutrition Research Reviews · doi:10.1017/s095442241400002x · Cited by 429
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K. V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Hepatology · doi:10.1002/hep.27242 · Cited by 379
“develop fatty liver.(15,16) Moreover, mice expressing high levels of the human mutant protein in the liver (PNPLA3 mice) had hepatic steatosis, whereas mice expressing the wild-type protein (PNPLA3 mice) had hepatic TG levels that were similar to nontransgenic littermates.”
BackgroundSelf-citationAnstee, Q. M., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.182 · Cited by 333
Alcohol effects on hepatic lipid metabolism
Jeon, S., & Carr, R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.r119000547 · Cited by 326
Adiponutrin Functions as a Nutritionally Regulated Lysophosphatidic Acid Acyltransferase
Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A. Y., Wongsiriroj, N., Nagy, H. M., Ivanova, P. T., Scott, S. A., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.008 · Cited by 316
Self-citationDAG tales: the multiple faces of diacylglycerol—stereochemistry, metabolism, and signaling
Eichmann, T. O., & Lass, A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1982-3 · Cited by 314
Huang, Y., Cohen, J. C., & Hobbs, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.290114 · Cited by 314
Pirazzi, C., Adiels, M., Burza, M. A., Mancina, R. M., Levin, M., Ståhlman, M., Taskinen, M.-R., Orho-Melander, M., Perman, J., Pujia, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.030 · Cited by 305
BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Trépo, E., Romeo, S., Zucman-Rossi, J., & Nahon, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.011 · Cited by 291
Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901974116 · Cited by 284
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis
Li, J. Z., Huang, Y., Karaman, R., Ivanova, P. T., Brown, H. A., Roddy, T., Castro-Perez, J., Cohen, J. C., & Hobbs, H. H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65179 · Cited by 283
Self-citationNonalcoholic Fatty Liver Disease
Carr, R. M., Oranu, A., & Khungar, V. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.003 · Cited by 280
The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells
Bruschi, F. V., Claudel, T., Tardelli, M., Caligiuri, A., Stulnig, T. M., Marra, F., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.29041 · Cited by 268
Ren, G., Kim, J. Y., & Smas, C. M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00084.2012 · Cited by 261
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
Anstee, Q. M., Seth, D., & Day, C. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.037 · Cited by 254
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252
Chiappini, F., Coilly, A., Kadar, H., Gual, P., Tran, A., Desterke, C., Samuel, D., Duclos-Vallée, J.-C., Touboul, D., Bertrand-Michel, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46658 · Cited by 246
Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C., & Hobbs, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719955 · Cited by 226
Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Santoro, N., Savoye, M., Kim, G., Marotto, K., Shaw, M. M., Pierpont, B., & Caprio, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037827 · Cited by 108
“In fact, while knock out mice for the pnpla3 do not show any increased fat accumulation into the liver with respect to the wild types [25,26], the administration through viral vectors of the mutated PNPLA3 confers to wild type mice a higher susceptibility to fatty liver [24].”
BackgroundJohnson, S. M., Bao, H., McMahon, C. E., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49224-x · Cited by 100
PNPLA3 expression and its impact on the liver: current perspectives
Bruschi, F. V., Tardelli, M., Claudel, T., & Trauner, M. (2017) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s125718 · Cited by 81
Muise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57
Genetic-related and carbohydrate-related factors affecting liver fat accumulation
Goran, M. I., Walker, R., & Allayee, H. (2012) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3283544477 · Cited by 30
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
Metadata
- Authors
- Basantani, M. K., Sitnick, M. T., Cai, L., Brenner, D. S., Gardner, N. P., Li, J. Z., Schoiswohl, G., Yang, K., Kumari, M., Gross, R. W., Zechner, R., & Kershaw, E. E.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 52
- Issue
- 2
- Pages
- 318-329
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2146632745
- Cited by
- 242
- References
- 11
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.